Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

GlaxoSmithKline Pharmaceuticals Ltd

NSE: GLAXO · BSE: 500660 · Pharmaceuticals & Biotechnology · 34 announcements

Share price
₹2,628.00
Market cap
₹44,520 Cr
Revenue (annual)
₹3,822 Cr
Net profit (annual)
₹1,036 Cr
P/E (TTM)
41.7×Sector 47.4×
Promoter holding
75.00%+0.00% QoQ
FII holding
4.79%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

11:11 IST NSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Limited appointed Mr. Vinay Subramanian as Commercial Head - Oncology, effective April 20, 2026. Mr. Subramanian brings 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology portfolio management and strategic business development in India.

10:50 IST NSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Limited has appointed Mr. Ronojit Biswas as an Executive Director for a three-year term starting April 1, 2026. A seasoned finance leader with over 25 years of global GSK experience, he previously served as CFO for GSK's Brazil and Vietnam operations.

Execution
36 months
10:31 IST BSE
Management Change

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Ltd appointed Mr. Vinay Subramanian as Commercial Head – Oncology and Senior Management Personnel, effective April 20, 2026. Subramanian brings over 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology business segment and strategic management team in Mumbai.

23:24 IST BSE
Annual General Meeting

GlaxoSmithKline Pharmaceuticals Annual General Meeting

GlaxoSmithKline Pharmaceuticals Ltd announced that shareholders approved the appointment of Mr. Ronojit Biswas as Director and Whole-time Director & CFO via postal ballot. The ordinary resolutions were passed with over 99.6% majority. This confirms leadership stability for the company's financial and administrative operations.